Get the Stockscreener App
1.45
4.61%
-0.07
Ocugen Inc stock is traded at $1.45, with a volume of 4.40M.
It is down -4.61% in the last 24 hours and up +5.84% over the past month.
Ocugen Inc company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. The company's pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, Inhaled Mucosal Vaccine Platform. The company is developing a modifier gene therapy platform designed to fulfill unmet medical needs related to retinal diseases, including inherited retinal diseases ("IRDs"), such as RP, LCA, Stargardt disease, and multifactorial diseases such as dAMD and Geographic Atrophy ("GA").
See More
Previous Close:
$1.52
Open:
$1.51
24h Volume:
4.40M
Relative Volume:
1.02
Market Cap:
$474.61M
Revenue:
-
Net Income/Loss:
$-63.08M
P/E Ratio:
-5.3704
EPS:
-0.27
Net Cash Flow:
$-72.53M
1W Performance:
-12.65%
1M Performance:
+5.84%
6M Performance:
+35.51%
1Y Performance:
+88.51%
1-Day Range:
$1.45
$1.54
1-Week Range:
$1.45
$1.65
52-Week Range:
$0.515
$1.96
Ocugen Inc Stock (OCGN) Company Profile
Name
Ocugen Inc
Sector
Industry
Phone
484-328-4701
Address
11 GREAT VALLEY PARKWAY, MALVERN, PA
Compare OCGN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
OCGN
Ocugen Inc
|
1.45 | 497.53M | 0 | -63.08M | -72.53M | -0.27 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.90 | 120.69B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.45 | 78.77B | 14.34B | 4.50B | 3.88B | 41.57 |
|
ARGX
Argen X Se Adr
|
840.50 | 52.46B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
338.06 | 45.82B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
340.38 | 38.73B | 4.98B | 69.59M | 525.67M | 0.5197 |
Ocugen Inc Stock (OCGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-15-24 | Initiated | Maxim Group | Buy |
| Mar-01-23 | Upgrade | Chardan Capital Markets | Neutral → Buy |
| Aug-23-22 | Initiated | Mizuho | Buy |
| Jun-15-22 | Resumed | ROTH Capital | Buy |
| Jun-02-22 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-26-21 | Initiated | Noble Capital Markets | Outperform |
| Jun-11-21 | Downgrade | ROTH Capital | Buy → Neutral |
| May-07-21 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Feb-09-21 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Feb-04-21 | Upgrade | H.C. Wainwright | Neutral → Buy |
View All
Ocugen Inc Stock (OCGN) Latest News
What are analysts price targets for Ocugen IncJuly 2025 Volume & Long Hold Capital Preservation Tips - baoquankhu1.vn
Valuation Update: Can Belite Bio Inc Depositary Receipt deliver alphaWeekly Market Outlook & Smart Allocation Stock Tips - baoquankhu1.vn
RSI Check: Can Ocugen Inc weather a recessionWeekly Trading Summary & Community Consensus Trade Alerts - baoquankhu1.vn
Ocugen’s Gene Therapy Candidate Shows Promise in Early-Stight Loss Trial - AD HOC NEWS
Ocugen’s Stargardt Gene Therapy OCU410ST Provides +6-Letter Gain in BCVA-Evaluable Patients in Phase 1 Trial - NeurologyLive
Ocugen stock surges 75% year to date: What's in store for 2026? - MSN
Ocugen Raises $20.9M to Extend Cash Runway Into Late 2026 - MyChesCo
Macro Review: Is Ocugen Inc forming a double bottom2025 Volatility Report & Growth Oriented Trading Recommendations - baoquankhu1.vn
Ocugen Stock: A Turnaround Fueled by Promising Trial Data - AD HOC NEWS
Ocugen’s Clinical Pipeline Takes Center Stage Following Capital Raise - AD HOC NEWS
How The Narrative Around Ocugen (OCGN) Is Shifting After The Latest Price Target Change - Yahoo Finance
Ocugen Secures Financial Runway Through Strategic Capital Raise - AD HOC NEWS
Ocugen Secures Funding to Advance Gene Therapy Pipeline - AD HOC NEWS
Ocugen Secures Funding at a Short-Term Cost to Shareholders - AD HOC NEWS
Ocugen Shares Defy Dilution Fears on Strong Clinical Data - AD HOC NEWS
Ocugen, Inc. Announces Closing of $22.5 Million Underwritten Registered Direct Offering of Common Stock - Sahm
Ocugen closes $22.5 million registered direct offering By Investing.com - Investing.com South Africa
Ocugen Secures Financial Runway Through 2026 - AD HOC NEWS
How Fresh Capital And Positive OCU410 Data At Ocugen (OCGN) Has Changed Its Investment Story - Yahoo Finance
Ocugen strengthens balance sheet with new equity financing - TipRanks
Ocugen, Inc. Closes $22.5 Million Stock Offering - TradingView
Ocugen closes $22.5 million registered direct offering - Investing.com
Ocugen (NASDAQ: OCGN) reports strong midstage data for gene therapy - MSN
Ocugen prices $22.5M common stock offering at $1.50 per share - MSN
Ocugen Announces $22.5 Million Public Stock Offering - The Globe and Mail
Ocugen (NASDAQ:OCGN) Trading 12.4% HigherTime to Buy? - MarketBeat
Ocugen Stock Faces Dilution After Capital Raise - AD HOC NEWS
Ocugen (NASDAQ: OCGN) Reports Strong Midstage Data for Gene Therapy - MyChesCo
Ocugen prices $22.5 million common stock offering at $1.50 per share - Investing.com Nigeria
Ocugen prices $22.5 million common stock offering at $1.50 per share By Investing.com - Investing.com South Africa
Ocugen Receives FDA Clearance for Phase 2/3 Trial of Genetic Therapy for Stargardt Disease - MSN
Ocugen Signs Underwriting Agreement With Oppenheimer & Co - TradingView
Form 424B5 Ocugen, Inc. - StreetInsider
Ocugen shares slide after company prices $22.5 million equity raise - MSN
Ocugen, Inc. Announces Pricing of $22.5 Million Offering of Common Stock - Ocugen, Inc.
Ocugen (OCGN) Prices $22.5 Million Stock Offering - GuruFocus
Ocugen drops on stock offering - TradingView
Ocugen (OCGN) Prices Stock Offering to Raise $22.5 Million - GuruFocus
Ocugen stock falls after pricing $22.5 million common share offering By Investing.com - Investing.com Nigeria
Ocugen stock falls after pricing $22.5 million common share offering - Investing.com
Ocugen Announces Pricing Of $22.5 Million Offering Of Common Stock - TradingView
Ocugen Strikes $187.5 Million Licensing Deal With Kwangdong for Gene Therapy in Korea - MSN
Ocugen (OCGN) Is Down 12.6% After Positive Phase 2 OCU410 Data in Geographic Atrophy - simplywall.st
Gene therapy slows vision loss in Stargardt trial, fueling hope for first treatment - MSN
Gene Therapy Slows Vision Loss in Stargardt Trial, Fueling Hope for First Treatment - mychesco.com
Ocugen's (OCGN) "Buy" Rating Reiterated at Chardan Capital - MarketBeat
OCGN Analyst Rating Maintains "Buy" with $7.00 Price Target | OC - GuruFocus
Aug Rallies: Is Ocugen Inc undervalued by DCF analysisEarnings Growth Report & Real-Time Volume Spike Alerts - baoquankhu1.vn
Ocugen, Inc. (NASDAQ:OCGN) Short Interest Update - MarketBeat
Ocugen Inc Stock (OCGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.27%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):